Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Anticancer Research|July 31, 2012
Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trialReiki Nishimura, Yoshiaki Rai, Fumie Matsuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
<i>CYP2D6</i> Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II StudyKenji Tamura, Chiyo K Imamura, Toshimi Takano, et al.
Clinical Breast Cancer|March 9, 2021
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA StudyTsutomu Takashima, Fumikata Hara, Takayuki Iwamoto, et al.
International Journal of Clinical Oncology|December 6, 2018
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patientsHirofumi Mukai, Chikako Shimizu, Norikazu Masuda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 16, 2012
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study]Keisei Anan, Maki Tanaka, Shoshu Mitsuyama, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|February 11, 2015
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer Research : BCR|May 29, 2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort studyTakashi Ishikawa, Yukari Uemura, Hirohito Seki, et al.
Breast Cancer (Tokyo, Japan)|April 29, 2005
Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumorsYoshifumi Komoike, Futoshi Akiyama, Yuichi Iino, et al.
Cancer|December 8, 2005
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastasesYoshifumi Komoike, Futoshi Akiyama, Yuichi Iino, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Anticancer Research|July 31, 2012
Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trialReiki Nishimura, Yoshiaki Rai, Fumie Matsuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
<i>CYP2D6</i> Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II StudyKenji Tamura, Chiyo K Imamura, Toshimi Takano, et al.
Clinical Breast Cancer|March 9, 2021
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA StudyTsutomu Takashima, Fumikata Hara, Takayuki Iwamoto, et al.
International Journal of Clinical Oncology|December 6, 2018
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patientsHirofumi Mukai, Chikako Shimizu, Norikazu Masuda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 16, 2012
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study]Keisei Anan, Maki Tanaka, Shoshu Mitsuyama, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|February 11, 2015
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer Research : BCR|May 29, 2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort studyTakashi Ishikawa, Yukari Uemura, Hirohito Seki, et al.
Breast Cancer (Tokyo, Japan)|April 29, 2005
Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumorsYoshifumi Komoike, Futoshi Akiyama, Yuichi Iino, et al.
Cancer|December 8, 2005
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastasesYoshifumi Komoike, Futoshi Akiyama, Yuichi Iino, et al.
Pageof 8